InthephaseIIIBILCAPtrialreportedinTheLancetOncology,JohnN.Primrose,FMedSci,andcolleaguesfoundevidencethatadjuvantcapecitabinemayimproveoverallsurvivalvsobservationfollowingsurgeryforpatientswithresectedbiliarytractcancer.
Theopen-labelstudyincludedpatientsfrom44UKsiteswithcholangiocarcinomaormuscle-invasivegallbladdercancerwhohadundergonemacroscopically